Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739898 | 0.80 | LMNA (0.40) | KDM4EALDH1A1DAOLMNAKMT2A | |
| SCHEMBL9373876 | 0.78 | CALM1 (0.44) | KDM4ETYMPALDH1A1DAOALKBH3 | |
| SCHEMBL20828256 | 0.76 | TYMP (0.65) | KDM4ETYMPALDH1A1DAOLMNA | |
| SCHEMBL1888814 | 0.73 | ALDH1A1 (0.60) | KDM4ETYMPALDH1A1LMNAHSD17B10 | |
| SCHEMBL6129257 | 0.72 | PDGFRA (0.49) | KDM4ETYMPALDH1A1LMNAHTT | |
| SCHEMBL6135082 | 0.72 | DAO (0.49) | KDM4ETYMPALDH1A1DAOLMNA | |
| SCHEMBL2257130 | 0.72 | DAO (0.49) | KDM4ETYMPALDH1A1DAOLMNA | |
| SCHEMBL5663531 | 0.71 | TNKS2 (0.49) | KDM4ETYMPALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL9454876 | 0.71 | PTGS2 (0.44) | KDM4ETYMPALDH1A1DAOLMNA | |
| SCHEMBL14942695 | 0.70 | ALKBH3 (0.45) | KDM4EALDH1A1DAOLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081459-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20050272733-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-6921761-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040266773-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6750350-B2 | THERAPY FOR SEXUAL DISORDERS | NEUROCRINE BIOSCIENCES, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1411941-A2 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | Neurocrine Biosciences, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030073693-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-04-17 | — | — | US | disclosed |
| WO-2003011293-A2 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266773-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | KDM4E 2303/4885TYMP 2548/4885ALDH1A1 2906/4885 |
| US-20050272733-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | KDM4E 2241/4885TYMP 2749/4885ALDH1A1 3158/4885 |
| US-20030073693-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | KDM4E 2303/4885TYMP 2548/4885ALDH1A1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.